CN102965341B - 人脐带间充质干细胞系及其建立方法和应用 - Google Patents
人脐带间充质干细胞系及其建立方法和应用 Download PDFInfo
- Publication number
- CN102965341B CN102965341B CN201210430912.3A CN201210430912A CN102965341B CN 102965341 B CN102965341 B CN 102965341B CN 201210430912 A CN201210430912 A CN 201210430912A CN 102965341 B CN102965341 B CN 102965341B
- Authority
- CN
- China
- Prior art keywords
- htert
- cell
- hmsc
- umbilical cord
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 33
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 29
- 238000010276 construction Methods 0.000 title claims abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract description 91
- 108010017842 Telomerase Proteins 0.000 claims abstract description 19
- 239000013598 vector Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims description 16
- 241000713666 Lentivirus Species 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 9
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 5
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000004069 differentiation Effects 0.000 abstract description 6
- 210000000130 stem cell Anatomy 0.000 abstract description 6
- 238000004113 cell culture Methods 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000008827 biological function Effects 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 14
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 11
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 11
- 208000005623 Carcinogenesis Diseases 0.000 description 10
- 230000036952 cancer formation Effects 0.000 description 10
- 231100000504 carcinogenesis Toxicity 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 238000011579 SCID mouse model Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004992 fission Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010020464 Humoral immune defect Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 238000013326 plasmid cotransfection Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210430912.3A CN102965341B (zh) | 2012-11-01 | 2012-11-01 | 人脐带间充质干细胞系及其建立方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210430912.3A CN102965341B (zh) | 2012-11-01 | 2012-11-01 | 人脐带间充质干细胞系及其建立方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102965341A CN102965341A (zh) | 2013-03-13 |
CN102965341B true CN102965341B (zh) | 2014-12-10 |
Family
ID=47795777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210430912.3A Expired - Fee Related CN102965341B (zh) | 2012-11-01 | 2012-11-01 | 人脐带间充质干细胞系及其建立方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102965341B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190038717A1 (en) * | 2016-02-04 | 2019-02-07 | Slbigen Inc. | Mesenchymal stem cell expressing hepatocyte growth factor, and use thereof |
CN116064677A (zh) * | 2016-02-05 | 2023-05-05 | 斯比根公司 | 表达trail和cd的间充质干细胞及其用途 |
CN107937442A (zh) * | 2017-11-13 | 2018-04-20 | 北京多赢时代科技有限公司 | 一种永生化人脂肪间充质干细胞系及其建立方法 |
CN109355262A (zh) * | 2018-06-13 | 2019-02-19 | 浙江生创精准医疗科技有限公司 | 永生化宫血干细胞系 |
CN110106201A (zh) * | 2019-04-03 | 2019-08-09 | 广州辉园苑医药科技有限公司 | 一种可控永生化的逆转录病毒载体和人脐带间充质干细胞及其构建方法 |
CN112048479A (zh) * | 2020-09-09 | 2020-12-08 | 金华职业技术学院 | 脐带间充质干细胞对高氧暴露肺和脑损伤保护的动物模型 |
CN112695015A (zh) * | 2020-12-18 | 2021-04-23 | 浙江卫未生物医药科技有限公司 | 一种永生化脐带间充质干细胞的制备方法及其外泌体制备方法和应用 |
CN112941034A (zh) * | 2021-04-08 | 2021-06-11 | 江苏易诺维生物医学研究院有限公司 | 一种永生化人脐带间充质干细胞系的构建方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101063150A (zh) * | 2007-04-24 | 2007-10-31 | 浙江大学 | 人端粒酶基因转导骨髓间充质干细胞的方法 |
-
2012
- 2012-11-01 CN CN201210430912.3A patent/CN102965341B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101063150A (zh) * | 2007-04-24 | 2007-10-31 | 浙江大学 | 人端粒酶基因转导骨髓间充质干细胞的方法 |
Non-Patent Citations (6)
Title |
---|
EB病毒潜伏膜蛋白和肿瘤的关系;梁贤明;《国际检验医学杂志》;20070131;第28卷(第1期);54-56 * |
hTERT介导脐带间充质干细胞实现永生化的研究;张赛等;《中华神经医学杂志》;20080430;第7卷(第4期);325-328 * |
张赛等.hTERT介导脐带间充质干细胞实现永生化的研究.《中华神经医学杂志》.2008,第7卷(第4期), * |
徐燕 等.端粒酶与骨髓间充质干细胞.《中国组织工程研究与临床康复》.2007,第11卷(第7期), * |
梁贤明.EB病毒潜伏膜蛋白和肿瘤的关系.《国际检验医学杂志》.2007,第28卷(第1期), * |
端粒酶与骨髓间充质干细胞;徐燕 等;《中国组织工程研究与临床康复》;20070218;第11卷(第7期);1353-1355 * |
Also Published As
Publication number | Publication date |
---|---|
CN102965341A (zh) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102965341B (zh) | 人脐带间充质干细胞系及其建立方法和应用 | |
Henle et al. | Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells | |
CN101942413B (zh) | 出生缺陷细胞库及其构建方法 | |
CN102127522B (zh) | 人脐带间充质干细胞及其制备方法 | |
Smiley et al. | Cytomegalovirus infection and viral‐induced transformation of human endothelial cells | |
CN102533659A (zh) | 诱导人脐带间充质干细胞分化为睾丸间质细胞的方法与应用 | |
Zhang et al. | Human diploid MRC-5 cells exhibit several critical properties of human umbilical cord-derived mesenchymal stem cells | |
CN109337858A (zh) | 用于乙肝病毒感染的原代肝细胞来源的肝前体样细胞模型、制备方法及应用 | |
CN108342362A (zh) | 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法 | |
Polanska et al. | Experimental generation of carcinoma-associated fibroblasts (CAFs) from human mammary fibroblasts | |
CN103667349A (zh) | 一种高效获取猪诱导性多能干细胞的方法 | |
CN101912618A (zh) | 携带nk4基因的骨髓间充质干细胞的制备方法及其应用 | |
CN108220243B (zh) | 一种多能干细胞及其分化的t细胞和应用 | |
CN102181399B (zh) | 一种cd133高表达鼠肝肿瘤细胞系及制备方法 | |
CN110229790A (zh) | 永生化人源神经干细胞系、制备方法、重组病毒载体及应用 | |
CN103923942B (zh) | 一种表达猪端粒酶反转酶转座子载体及其构建方法与在建立猪永生化细胞系中的应用 | |
CN104805122A (zh) | Runx2重组慢病毒感染骨髓间充质干细胞表达成骨基因的方法 | |
CN102057038B (zh) | 用于以高品质和高数量制造重组蛋白的人类宿主细胞 | |
US20200385680A1 (en) | Immortalized sweat gland myoepithelial cell | |
CN105062973A (zh) | 一株携带tp53突变的hpv阴性阴茎鳞癌细胞系及其用途 | |
CN101555487A (zh) | 用于骨质疏松症的rna干扰载体及大鼠骨髓间质干细胞 | |
CN114525238A (zh) | 一株牛皮肤成纤维永生化细胞系的建立方法及应用 | |
CN104928319A (zh) | hTERT慢病毒重组体永生化人牙周膜干细胞系的方法 | |
CN115433718B (zh) | 一种永生化口腔上皮细胞及其制备方法和应用 | |
CN109680000A (zh) | 利用树鼩骨髓间充干细胞建立hcv细胞模型的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING INDUSTRY UNIVERSITY CENG YI TENG ZHIPING H Free format text: FORMER OWNER: BEIJING INDUSTRY UNIVERSITY CENG YI HAO YANZHE TENG ZHIPING Effective date: 20130313 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zeng Yi Inventor after: Teng Zhiping Inventor after: Hao Yanzhe Inventor after: Ma Jing Inventor after: Zhang Xiaomei Inventor after: Li Dongsheng Inventor before: Zeng Yi Inventor before: Hao Yanzhe Inventor before: Teng Zhiping Inventor before: Ma Jing Inventor before: Zhang Xiaomei Inventor before: Li Dongsheng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CENG YI HAO YANZHE TENG ZHIPING MA JING ZHANG XIAOMEI LI DONGSHENG TO: CENG YI TENG ZHIPING HAO YANZHE MA JING ZHANG XIAOMEI LI DONGSHENG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130313 Address after: 100052 Beijing city Xuanwu District New Street No. 100 Applicant after: National Institue For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention Applicant after: Beijing University of Technology Applicant after: Zeng Yi Applicant after: Teng Zhiping Applicant after: Hao Yanzhe Address before: 100052 Beijing city Xuanwu District New Street No. 100 Applicant before: National Institue For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention Applicant before: Beijing University of Technology Applicant before: Zeng Yi Applicant before: Hao Yanzhe Applicant before: Teng Zhiping |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141210 Termination date: 20171101 |